Piper Sandler Maintains Overweight on Madrigal Pharmaceuticals, Raises Price Target to $336
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Yasmeen Rahimi has maintained an Overweight rating on Madrigal Pharmaceuticals (NASDAQ:MDGL) and increased the price target from $305 to $336.
January 24, 2024 | 2:42 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler's analyst Yasmeen Rahimi has reaffirmed an Overweight rating on Madrigal Pharmaceuticals and raised the price target to $336, indicating a positive outlook on the stock.
The increase in price target by Piper Sandler suggests a strong conviction in the future performance of Madrigal Pharmaceuticals. This positive analyst rating typically instills confidence in investors and can lead to a short-term increase in the stock price as market participants react to the news.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100